| 摘要 |
The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.; |
| 主权项 |
1. A compound having the structure of Formula (I), or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, wherein R1 represents optionally substituted groups selected from linear or branched (C1-C6)alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl or the groups C(O)OR3, C(O)R3, and SO2R3, wherein R3 represents H, or optionally substituted groups selected from linear or branched (C1-C6)alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl groups; ‘Z’ when present represents an optionally substituted single or fused group selected from aryl, heteroaryl, heterocyclyl, cycloalkyl groups; ‘Y’ represents either a bond or groups selected from oxygen, —NH, S, SO, SO2 or NR4, wherein R4 represents, linear or branched (C1-C6)alkyl; ‘X’ and ‘W’ may be same or different & independently represents C or N; ‘m’ ‘n’ and ‘p’ independently represents an integer ranging from 0 to 4; and R2 may be optionally present and when present represents an oxo group. |
